A woman looking into a mirror, smiling, wearing a white sports bra and brown pants, with a white lamp and dark curtains in the background.

Weight Management Services:
Tirzepatide and Semaglutide

Transform Your Health with Medical Weight Management

We offer the latest FDA-approved weight loss medications—tirzepatide (Zepbound®, Mounjaro®) and semaglutide (Wegovy®, Ozempic®)—as well as compounded formulations of tirzepatide and semaglutide. Combined with personalized nutrition guidance and lifestyle support, our approach helps you achieve lasting, sustainable results.

Available Medications

Semaglutide (Wegovy®, Ozempic®)

  • Once weekly injection

  • Doses range from 0.25 mg to 2.4 mg

  • Average weight loss: 13 to 16% of body weight over 68 to 72 weeks

  • Also available as a daily oral tablet (Rybelsus, Wegovy oral)

Tirzepatide (Zepbound®, Mounjaro®)

  • Once weekly injection

  • Doses range from 2.5 mg to 15 mg

  • Average weight loss: 15 to 21% of body weight over 72 weeks

  • May offer additional benefits for blood sugar control

Both medications are FDA approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight related health condition.

"Working with Jessica has been an absolute pleasure, I've lost over 100lbs and I have her to thank for that! She's supportive, listens, and understands. I can't recommend her enough!"

- David B.

Getting Started

Person in a white t-shirt showing empty pockets, indicating they have no money.

Your Journey to Better Health

Successful weight management with these medications requires a comprehensive approach combining medication, nutrition, physical activity, and behavioral support. Our team is here to guide you every step of the way, helping you achieve and maintain meaningful weight loss while improving your overall health.

Ready to Get Started?

Contact us today to schedule a consultation and learn if tirzepatide or semaglutide is right for you.

TReferences

  1. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. Aronne LJ, Horn DB, le Roux CW, et al. The New England Journal of Medicine. 2025;393(1):26-36. doi:10.1056/NEJMoa2416394.

  2. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. Mozaffarian D, Agarwal M, Aggarwal M, et al. The American Journal of Clinical Nutrition. 2025;122(1):344-367. doi:10.1016/j.ajcnut.2025.04.023.

  3. Managing Adverse Effects of Incretin-Based Medications for Obesity. Kushner RF, Almandoz JP, Rubino DM. JAMA. 2025;:2836876. doi:10.1001/jama.2025.11153.

  4. Integrating Diet and Physical Activity When Prescribing GLP-1s—Lifestyle Factors Remain Crucial. Mehrtash F, Dushay J, Manson JE. JAMA Internal Medicine. 2025;185(9):1151-1152. doi:10.1001/jamainternmed.2025.1794.

  5. Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review. Honigberg MC, Chang LS, McGuire DK, et al. JAMA Cardiology. 2020;5(10):1182-1190. doi:10.1001/jamacardio.2020.1966.

  6. Obesity Management in Adults: A Review. Elmaleh-Sachs A, Schwartz JL, Bramante CT, et al. JAMA. 2023;330(20):2000-2015. doi:10.1001/jama.2023.19897.

  7. Glucagon-Like Receptor Agonists and Next-Generation Incretin-Based Medications: Metabolic, Cardiovascular, and Renal Benefits. Nauck MA, Tuttle KR, Tschöp MH, Blüher M. Lancet (London, England). 2026;:S0140-6736(25)02105-1. doi:10.1016/S0140-6736(25)02105-1.